Afatinib’s distinctive anticancer therapeutic benefit—its irreversible binding to ErbB family receptors—offers higher potential to suppress the proliferation of a wide class of tumor cells and greater efficacy than the first-generation EGFR-TKIs [12]. The gene discussed is EGFR; the disease is neoplasm.